丹蒌片治疗冠心病稳定型心绞痛（痰瘀互结证）心电图分析及中医证候的疗效观察

发布时间：2018-06-07 13:49

本文选题：丹蒌片 + 冠心病　；参考：《黑龙江中医药大学》2017年硕士论文

【摘要】：目的:本观察为应用丹蒌片治疗冠心病稳定型心绞痛,证属痰瘀互结证患者的心电图表现、中医证候疗效及硝酸甘油停减率的疗效分析,初步评价丹蒌片临床应用的有效性及安全性。方法:选取2016年4月～2016年11月在黑龙江中医药大学附属第一医院心内科门诊的患者,符合慢性稳定型心绞痛诊断标准的患者60例。根据治疗组和对照组3:1的比例,通过采用随机、双盲、阳性对照的方法分为治疗组45人,对照组15人。治疗组:丹蒌片,5片/次,3次/日;利脑心胶囊模拟剂,4粒/次,3次/日,均餐后服用。对照组:利脑心胶囊,4粒/次,3次/日;丹蒌片模拟剂,5片/次,3次/日,均餐后服用。观察两组患者治疗前后心电图变化、中医证候积分改变、中医症状疗效、硝酸甘油用量变化、以及相关安全性指标。结果:1、两组患者的心电图疗效相比无显著性差异(P0.05),但治疗组疗效略优于对照组。2、两组患者中医症状单项计分,中医症状积分,中医证候疗效相比较,P0.05,两组差异性显著,治疗组优于对照组。3、两组患者治疗后硝酸甘油停减率比较,P0.05,具有统计学意义,治疗组优于对照组。4、安全性指标:治疗组和对照组组内用药前后药物安全性检测值未见明显变化,差异无统计学意义(P0.05);疗后组间药物安全性检测值未见明显变化,差异无统计学意义(P0.05)。结论:1、丹蒌片可以改善冠心病稳定型心绞痛(痰瘀互结证)患者的中医证候。2、丹蒌片可以减少冠心病稳定型心绞痛(痰瘀互结证)患者硝酸甘油的使用量。3、丹萎片对冠心病稳定型心绞痛(痰瘀互结证)患者的心电图改善不明显。4、丹蒌片在治疗过程中未发现不良反应,安全性显著。
[Abstract]:Objective: to observe the effect of Danlou tablet on stable angina pectoris of coronary heart disease, electrocardiogram manifestation of syndrome of phlegm and blood stasis, curative effect of TCM syndromes and stopping and decreasing rate of nitroglycerin. To evaluate the efficacy and safety of Danlou tablet in clinical application. Methods: from April 2016 to November 2016, 60 patients with chronic stable angina pectoris were selected from the Department of Cardiology, the first affiliated Hospital of Heilongjiang University of traditional Chinese Medicine. According to the ratio of 3:1 in the treatment group and the control group, 45 patients in the treatment group and 15 in the control group were divided into treatment group and control group by random, double-blind and positive control methods. In the treatment group, 5 tablets of Dangluo tablet / 3 times a day, 4 tablets of Liniaoxin capsule analogue, 3 times a day, were taken after meal. In the control group, 4 capsules of Lineau Xin capsule were taken 3 times a day, and 5 tablets of Danglou tablet were taken after meal. The changes of electrocardiogram (ECG), the integral change of TCM syndromes, the curative effect of TCM symptoms, the dosage of nitroglycerin and the related safety indexes were observed before and after treatment. Results there was no significant difference in electrocardiogram effect between the two groups (P 0.05), but the curative effect of the treatment group was slightly better than that of the control group (P 0.05). There was a significant difference between the two groups in the single score of TCM symptoms, the score of TCM symptoms, and the curative effect of TCM syndromes. The treatment group was superior to the control group (.3), the reduction rate of nitroglycerin in the two groups was significantly higher than that in the control group (P0.05), the treatment group was better than the control group (.4), the safety index: there was no significant change in the safety of the drug before and after treatment in the treatment group and the control group. There was no significant difference between the two groups (P 0.05), but there was no significant difference in drug safety between the two groups (P 0.05). Conclusion 1, Danlou tablet can improve TCM syndromes of stable angina pectoris of coronary heart disease (phlegm and blood stasis syndrome). Danlou tablet can reduce the usage of nitroglycerin in patients with stable angina pectoris of coronary heart disease (phlegm and blood stasis mutual knot syndrome), and can reduce the usage of nitroglycerin in patients with stable angina pectoris of coronary heart disease. The electrocardiogram of patients with stable angina pectoris of coronary heart disease (phlegm and blood stasis syndrome) was not improved significantly. Safety is remarkable.
【学位授予单位】：黑龙江中医药大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R541.4

【参考文献】